ArticleProbiotics and antimicrobial proteins2026
Protective Effects of Limosilactobacillus reuteri MSMC64 in Hyperlipidemia Rats Induced by a High-Cholesterol Diet.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multifunctional antimicrobial effects ofFrontiers in immunology · 2026Article
- Probiotics and human health: biological activities, nutritional aspects, immunomodulatory properties, applications, and future perspectives - a comprehensive review.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hyperlipidemia, characterized by abnormally elevated levels of lipids such as cholesterol, is a significant risk factor for cardiovascular diseases (CVD), contributing to increased oxidative stress, inflammation, and disruption of gut immunity. Dysbiosis, or imbalance in the gut microbiome, plays a critical role in the pathogenesis of hyperlipidemia. Probiotics, as key components of the gut microbiome, have been shown to positively impact health. This study aimed to evaluate the effects of Limosilactobacillus reuteri MSMC64 on lipid profiles, blood glucose levels, hepatic steatosis, antioxidant capacity, inflammatory biomarkers, and colon barrier immunity in hyperlipidemic rats induced by a high-cholesterol diet. The results demonstrated that the administration of L. reuteri MSMC64 may improve lipid profiles and blood glucose levels, reduce hepatic steatosis and oxidative stress, and lower inflammatory biomarkers while maintaining colon barrier integrity. These findings suggest that L. reuteri MSMC64 has the potential to be developed as a probiotic supplement for mitigating risk factors associated with hyperlipidemia and CVD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.